London-listed blood disease specialist Hemogenyx Pharmaceuticals (LSE: HEMO) has provided an update on the development of its lead product candidate, a CDX bispecific antibody.
While the firm had been in negotiations with an undisclosed global pharmaceutical company regarding further development, that firm has now declined to take the project further, Hemogenyx said on Wednesday.
The announcement caused shares in the company to fall almost 40% in pre-market trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze